Lung-Disease Focused AN2 Therapeutics Files Plans For NASDAQ Debut

AN2 Therapeutics Inc filed plans on Friday to go public in an initial public offering in which it reportedly hopes to raise about $75 million.
AN2 plans to list on the Nasdaq with the symbol of ANTX.
The Menlo Park-based biotech is developing a therapy for non-tuberculous mycobacterial (NTM) lung disease, which typically attacks older people or those with a weakened immune system.
See the IPO prospectus here.
Its initial product candidate is epetraborole, a once-daily oral treatment for patients with NTM.
The Company licensed exclusive worldwide development and commercialization rights for epetraborole from Anacor Pharmaceuticals, owned by Pfizer Inc PFE, in 2016.
AN2 Therapeutics plans to conduct a Phase 2/3 trial in treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common type of NTM lung disease.
The trial design is currently under review from the FDA, and the Company plans to initiate enrollment in the 1H22, with topline results for the Phase 2 part expected in mid-2023.